DexCom, Inc. (DXCM)
Last Price$86.0(2.7%)
Market Cap$34.9B
DXCM Rating
DXCM Quality rating performance
DXCM Intrinsic Value
Key Highlights:
As of Mar 03, 2025 DXCM Relative Value is $48.2, which is overvalued by 43.9%, compared to current share price of $86.0.
As of Mar 03, 2025 DXCM DCF Value is $39.0, which is overvalued by 54.7%, compared to current share price of $86.0.
DXCM Share Price History
1W (5.2%)
1M (1.2%)
6M 18.8%
YTD (30.1%)
1Y (29.7%)
3Y (18.9%)
5Y 26.0%
10Y 482.6%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
DXCM Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$34.9B
$34.9B
$4,033.0M
$453.9M
Shares Outstanding
406M
Employees
N/A
Growth (CAGR)
22.3%
33.3%
39.83%
27.5%
14.3%
42.16%
Profitability
60.4%
14.9%
14.3%
17.1%
11.3%
78.8%
Intrinsic Value
$43.1 (49.8% overvalued)
$38.9
$47.4
17.2%
Return on Capital
Financial Health
$2,579.4M
($50.5M)
(0.1x)
42.6x
120.3%
Dividends
Earnings
Apr 23, 2025
BEAT by 0.4%
BEAT by 2.2%
(13.5%)
9 Beat & 1 Miss
DXCM Stock Financials
DXCM Income Statement Metrics
Annual
Quarterly
LTM
DXCM Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$0.0 -8.1% YoY
Capital Expenditure (CAPEX)
$0.0 -1.0% YoY
Free Cash Flow (FCF)
$0.0 -11.3% YoY
DXCM Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$4,033.0M 11.3% YoY
Cost of revenue
$1,567.3M 17.5% YoY
Pre-tax income
$709.0M (0.2%) YoY
17.6% margin
DXCM Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$6,484.5M
Current assets ($4,301.4M, 66.3% of total)
$2,579.4M (39.8%)
$1,005.7M (15.5%)
Other current assets
$716.3M (11.0%)
Non-current assets ($2,183.1M, 33.7% of total)
$0.0 (0.0%)
$1,402.7M (21.6%)
$103.4M (1.6%)
Other non-current assets
$677.0M (10.4%)
Financial position
($50.5M)
Cash & Short-term
Investments
Total Debt
DXCM Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
DXCM Earnings Surprises
Crunching data... Almost there!
DXCM Dividends
DXCM Dividend Yield
Crunching data... Almost there!
DXCM Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with DXCM
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
FAQ
What is DexCom, Inc. (DXCM) stock rating?
As of today, DexCom, Inc. has a stock rating of 7 (out of 10), which is considered Great.
is DexCom, Inc. (DXCM) a good stock to buy?
As of today, DexCom, Inc. has a Great stock rating, which is 49.8% overvalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 0.5%.